Gastrointestinal symptoms that some patients experience during treatmentsuch as nausea, constipation, or diarrheatypically improve as the drug clears from your system, with variable resolution timeframes among individuals
Ongoing advancements aim to reduce these side effects while preserving therapeutic effectiveness
Continued advances in next-generation GLP-1 medicines are expanding treatment options and transforming the future of metabolic disease management
The FDA has not approved this drug for treating obesity
Mutagenesis 28:555559 Blaikie L, Kay G, Maciel P, Kong Thoo Lin P (2022) Experimental modelling of Alzheimers disease for therapeutic screening
Because of this, allulose isn't approved for general sale in Canada, Europe, and Australia